The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01E | Protein kinase inhibitors | |
4
|
L01EC | B-Raf serine-threonine kinase (BRAF) inhibitors | |
5
|
L01EC04 |
| Active Ingredient |
|---|
|
Tovorafenib is a Type II RAF kinase inhibitor of mutant BRAF V600E, wild-type BRAF, and wild-type CRAF kinases. Tovorafenib exhibited antitumor activity in cultured cells and xenograft tumor models harboring BRAF V600E and V600D mutations, and in a xenograft model harboring a BRAF fusion. |
| Document | Type | Information Source | |
|---|---|---|---|
| OJEMDA Tablet / Oral suspension | MPI, US: SPL/PLR | FDA, National Drug Code (US) |